AUROBINDO

PRESS RELEASE

24th May 2011

Aurobindo Pharma receives final approval for Piperacillin and Tazobactam for Injection

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Piperacillin and Tazobactam for Injection 2.25g, 3.375g and 4.5g, packaged in single use vials.

Piperacillin and Tazobactam for Injection 2.25g, 3.375g and 4.5g are the generic equivalent of Wyeth's Zosyn® Injection 2.25g, 3.375g and 4.5g Piperacillin and Tazobactam for Injection consists of a semi-synthetic penicillin and a beta-lactamase inhibitor and is indicated for the treatment of moderate to severe systemic and/or local bacterial infections in which betalactamase producing bacteria are suspected or have been detected, such as nosocomial pneumonia, complicated urinary tract infections (including pyelonephritis), intra-abdominal infections, skin and soft tissue infections, bacterial infections in neutropenic adults and bacterial infections in neutropenic children aged 2-12 years. The strengths has a market size of approximately US$ 635 Million for the twelve months ending September 2010 according to IMS and will be launched soon.

Aurobindo Piperacillin and Tazobactam is the third generic product approved in the US.

Aurobindo now has a total of 136 ANDA approvals (105 Final approvals and 31 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com